Project ALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine…

Basic data

Title:
ALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Duration:
21/03/2016 to 20/03/2019
Abstract / short description:
ALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Keywords:
clinical trial
klinische Studie

Staff

Managers

Faculty of Medicine
University of Tübingen

Local organizational units

Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Help

will be deleted permanently. This cannot be undone.